tradingkey.logo
tradingkey.logo

Regentis Biomaterials Ord Shs

RGNT
3.000USD
-0.149-4.74%
Close 03/30, 16:00ETQuotes delayed by 15 min
0.00Market Cap
--P/E TTM

Regentis Biomaterials Ord Shs

3.000
-0.149-4.74%

More Details of Regentis Biomaterials Ord Shs Company

Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.

Regentis Biomaterials Ord Shs Info

Ticker SymbolRGNT
Company nameRegentis Biomaterials Ltd
IPO dateDec 04, 2025
CEOHazum (Eli)
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
Address60, Medinat Hyahudim
CityHERZLIYA
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryIsrael
Postal code4676652
Phone97246265502
Websitehttps://www.regentis.co.il/
Ticker SymbolRGNT
IPO dateDec 04, 2025
CEOHazum (Eli)

Company Executives of Regentis Biomaterials Ord Shs

Name
Name/Position
Position
Shareholding
Change
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Dr. Ehud Geller, Ph.D.
Dr. Ehud Geller, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Eli Hazum
Dr. Eli Hazum
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Arie Gordashnikov, CPA
Mr. Arie Gordashnikov, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jeff Dykan, CPA
Mr. Jeff Dykan, CPA
Director
Director
--
--
Dr. Susan Alpert, M.D., Ph.D.
Dr. Susan Alpert, M.D., Ph.D.
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Catherine C. (Keith) Valentine
Mr. Catherine C. (Keith) Valentine
Independent Director
Independent Director
--
--
Mr. Efraim Cohen-Arazi
Mr. Efraim Cohen-Arazi
Independent Director Nominee
Independent Director Nominee
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Dr. Ehud Geller, Ph.D.
Dr. Ehud Geller, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Eli Hazum
Dr. Eli Hazum
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Arie Gordashnikov, CPA
Mr. Arie Gordashnikov, CPA
Chief Financial Officer
Chief Financial Officer
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Mon, Mar 16
Updated: Mon, Mar 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
HaisThera Scientific Fund I, L.P
11.90%
Vitalife Life Sciences Venture Capital
7.74%
Ocorian Fund Management S.a.r.l
5.72%
Medica Venture Partners
5.05%
DSM Venturing B.V.
5.04%
Other
64.54%
Shareholders
Shareholders
Proportion
HaisThera Scientific Fund I, L.P
11.90%
Vitalife Life Sciences Venture Capital
7.74%
Ocorian Fund Management S.a.r.l
5.72%
Medica Venture Partners
5.05%
DSM Venturing B.V.
5.04%
Other
64.54%
Shareholder Types
Shareholders
Proportion
Corporation
17.63%
Venture Capital
12.78%
Hedge Fund
5.43%
Private Equity
5.05%
Individual Investor
1.42%
Other
57.69%

Institutional Shareholding

Relevant data have not been disclosed by the company yet.
Reporting Period
No. of institutions
Shares Held
Proportion
Change
No Data

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
No Data
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI